Biotherapeutic firm launches valley fever study
Prescott, Ariz. -- Imulan Biotherapeutics announced a study to test the effectiveness of a new immuno-therapeutic to treat dogs with coccidiodomycosis, or valley fever.
Prescott, Ariz.
-- Imulan Biotherapeutics announced a study to test the effectiveness of a new immuno-therapeutic to treat dogs with
coccidiodomycosis
, or valley fever.
Valley fever is an infection caused by the Coccidoides fungus and affects many species, including dogs and humans. The Southwest, specifically Arizona, is the primary area of infection in the United States.
The study will allow researchers to compare immunological vs. antifungal treatments in dogs to see how the treatments will work against human valley fever.
From poultry to public health: Understanding the H5N1 threat
October 29th 2024Veterinary and public health officials share the important roles of surveillance and prevention strategies, insights on the virus's transmission pathways, historical context, the One Health approach, and highlights effective precautionary measures to mitigate H5N1 risks.
Read More
FDA approves oral drug for broad canine protection against parasites
October 7th 2024Elanco's lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets (Credelio Quattro) provide a single monthly dose for protection against fleas, ticks, heartworms, roundworms, hookworms, and 3 species of tapeworm.
Read More
